Digital health assessment platform for neurology and Parkinson’s Disease
Digital biomarkers can identify and measure clinically relevant signals in neurological conditions. Learn more about the solution for clinical trials from Roche.
Digital health assessment platform for neurology and Parkinson’s Disease
Digital biomarkers can identify and measure clinically relevant signals in neurological conditions. Learn more about the solution for clinical trials from Roche.
Why sensitive and objective measurements matter
365 days in the life of a patient
People living with neurological conditions, such as Parkinson’s disease, may not entirely recall the manifestation and severity of the disease symptoms during periodic in-clinic visits.
Occasional in-clinic assessments over the span of months are subject to poor inter and intra-rater reliability.
Benefits of remote at-home digital assessment solution for life science and clinical trial sponsors
Remote, at-home digital assessments offer continuous data collection and may yield more meaningful insights – and provide greater sensitivity – for clinical trial researchers.1-2
A complete clinical trial solution to support therapeutic development
Remote assessment platform collects, stores and processes digital clinical data to support clinical trial research particularly for motor disorders and neurological conditions, such as Parkinson’s disease:
Roche Digital Biomarker Assessment Suite
Subjects do active in-clinic tests under supervision, and active and passive monitoring as part of their at-home daily routine.
Digital Health Tool with clinical trial services
The solution is designed to support patient and site workflows in clinical trials, complete with technology, data collection, and analytics.
Pathway to the future
More than 14,000 months of Parkinson’s disease data with extensive use in clinical trials and more than 50 scientific publications, posters, and presentations since 2015.* Researchers and clinical trial sponsors now have access to the Roche Digital Biomarker Solution to accelerate their own research.
*View the Publication table
References & notes
- Dorsey ER, Venuto C, Venkataraman V, Harris DA, Kieburtz K. Novel methods and technologies for 21st-century clinical trials: a review. JAMA Neurol. 2015 May;72(5):582–8.
- Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement disorder society UPDRS revision task force. movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15;23(15):2129–70.
Disclaimer
The Roche Digital Biomarker Solution for Parkinson’s disease is intended to collect, store and process digital clinical data to support exploratory research in clinical trials. This solution is not meant to be used for diagnosis and treatment decision making for individual patients.